Mast Cell Tumors Treatment Market Overview (2022 to 2032)
The global mast cell tumors treatment market size is expected to reach US$ 5.1 Billion in 2022 and US$ 7.9 Billion in 2032. It is projected to exhibit growth at a remarkable CAGR of 3.6% in the forecast period from 2022 to 2032. The increasing diagnosis rate of this condition among pet animals is anticipated to spur the demand for mast cell tumor treatment options in the forthcoming years.
Attribute
Details
Mast Cell Tumors Treatment Market Estimated Base Year Value (2021)
US$ 4.3 Billion
Mast Cell Tumors Treatment Market Expected Market Value (2022)
US$ 5.1 Billion
Mast Cell Tumors Treatment Market Anticipated Forecast Value (2032)
Mast cells are referred to as a type of white blood cell that is primarily found in several tissues of the body. These are considered to be allergy cells that play a significant role in the allergic response.
Mast cells often release compounds and chemicals, which is a process called degranulation when exposed to allergens. Histamine, which is one of the compounds, is commonly known to cause runny nose and eyes, sneezing, and itchiness.
A mast cell tumor, on the other hand, is a type of malignant tumor that forms nodules in the skin. It can also affect other parts of the body, such as the bone marrow, intestine, liver, and spleen. It is very common in dogs and most dogs living with this condition develop only one tumor.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Which are Some Prominent Drivers Spearheading Mast Cell Tumors Treatment Market Growth?
The availability of data regarding the disease is projected to augment the global mast cell tumor treatment market growth in the assessment period. The treatment approach towards this disease is expected to improve with the easy availability of data.
In addition to that, increasing awareness regarding mast cell tumors through social media platforms, non-government and government agencies, and advocacy groups are set to accelerate the growth in this market. The improved treatment-seeking rate and better rate of diagnosis are a couple of other factors that are likely to drive the market.
What are the Challenges Faced by the Mast Cell Tumors Treatment Industry?
In emerging countries, such as India, China, Indonesia, Brazil, and Iran, the lack of knowledge regarding various diseases affecting pet animals may hamper the sales of mast cell tumor treatment options. Also, people living in these countries may not be able to afford the expensive treatment options available in hospitals.
Find your sweet spots for generating winning opportunities in this market.
Why is North America Emerging as an Opportunistic Mast Cell Tumors Treatment Market?
The increasing prevalence of skin tumors in cats and dogs, especially in the USA and Canada is projected to bolster the North American mast cell tumor treatment market share in future years. As per the American College of Veterinary Surgeons (ACVS), mast cell tumors represent around 14–21% of all skin tumors that are diagnosed in dogs. Though these mainly occur in middle-aged patients, these sometimes occur in patients of any age group.
Governments of developed countries in this region are investing huge sums in clinical research activities to help companies in introducing cutting-edge treatment options. Currently, veterinary oncologists recommend surgery to cure lower-grade tumors, while higher-grade tumors are treated with a combination of chemotherapy and surgery.
How is Europe Contributing to Growth of the Mast Cell Tumors Treatment Market?
The rising prevalence of mast cell tumors in pet animals and the increasing awareness regarding the same in the United Kingdom and Germany are anticipated to bode well for the Europe mast cell tumor treatment market size. According to the 2021 PDSA Animal Wellbeing (PAW) Report, approximately 26% of the population in the United Kingdom own a dog with an estimated population of 9.6 million pet dogs. Also, 24% of the population in the country owns a cat with an estimated population of 10.7 million pet cats. These numbers are likely to surge at a rapid pace, thereby boosting the regional market.
A study published in the National Center for Biotechnology Information (NCBI) mentions that between July 2007 and June 2013, electronic patient records from healthcare professionals participating in the VetCompass animal surveillance project in the United Kingdom were evaluated for the diagnosis of mast cell tumors. Out of 168,636 dogs, around 453 had this condition. Boxers, golden retrievers, and Weimaraners had the highest prevalence at 1.95%, 1.39%, and 0.85%, respectively. Spurred by the aforementioned factors, the market in Europe is anticipated to surge at a fast pace.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need and save 40%!
Market Competition
Some of the renowned companies present in the mast cell tumors treatment market include Merck & Co. Inc., Pfizer Inc., EPI Health, LLC, Teva Pharmaceutical Industries Ltd., Bausch Health Companies Inc., Novartis AG, Mylan NV, Bayer AG, Sanofi S.A., and Johnson & Johnson among others.
The global market is moderately competitive and houses numerous key players. With the surging prevalence of mast cell tumors, many companies are striving to come up with novel treatment methods. To do so, they are consistently investing huge sums in exhaustive research and development activities. Meanwhile, a few other start-up companies are aiming to enter the untapped areas to raise awareness and sell their new products to patients.
Report Scope
Report Attribute
Details
Growth Rate
CAGR of 3.6% from 2022 to 2032
Base Year for Estimation
2021
Historical Data
2015 to 2020
Forecast Period
2022 to 2032
Quantitative Units
Revenue in USD Million, Volume in Kilotons, and CAGR from 2022 to 2032
Report Coverage
Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis
Segments Covered
Drug Class
Route of Administration
Distribution Channel
Region
Regions Covered
North America
Latin America
Western Europe
Eastern Europe
Asia Pacific Excluding Japan
Japan
Middle East and Africa
Key Countries Profiled
USA
Canada
Brazil
Argentina
Germany
United Kingdom
France
Spain
Italy
Nordics
BENELUX
Australia & New Zealand
China
India
ASIAN
GCC Countries
South Africa
Key Companies Profiled
Merck & Co. Inc.
Pfizer Inc.
EPI Health, LLC
Teva Pharmaceutical Industries Ltd.
Bausch Health Companies Inc.
Novartis AG
Mylan NV
Bayer AG
Sanofi S.A.
Johnson & Johnson
Customization
Available Upon Request
Key Segments Profiled in the Mast Cell Tumors Treatment Industry Survey
By Drug Class:
Antihistamines
Epinephrine
Steroids
Mast-cell Stabilizers
By Route of Administration:
Oral
Injectables
Topical
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Drug Stores
Online Pharmacies
By Region:
North America
Latin America
Western Europe
Eastern Europe
Asia Pacific Excluding Japan
Japan
Middle East and Africa
Frequently Asked Questions
What is the projected size of the global mast cell tumors treatment market by 2032?
The global mast cell tumors treatment market is anticipated to surpass US$ 7.9 Billion in 2032.
Which region is likely to lead the mast cell tumors treatment market?
North America is likely to lead the mast cell tumors treatment market in the forecast period.
Which are some of the renowned companies in the mast cell tumors treatment market?
Merck & Co. Inc., Pfizer Inc., EPI Health, LLC, Teva Pharmaceutical Industries Ltd., Bausch Health Companies Inc., and Novartis AG are some of the renowned companies in the mast cell tumors treatment market.
Table of Content
1. Executive Summary| Mast Cell Tumors Treatment Market
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. Value Chain Analysis
3.5.1. Profit Margin Analysis
3.5.2. Service Providers
3.6. PESTLE and Porter’s Analysis
3.7. Regulatory Landscape
3.7.1. By Key Regions
3.7.2. By Key Countries
3.8. Regional Parent Market Outlook
4. Global Market Analysis 2017 to 2021 and Forecast, 2022 to 2032
4.1. Historical Market Size Value (US$ Million) Analysis, 2017 to 2021
4.2. Current and Future Market Size Value (US$ Million) Projections, 2022 to 2032
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Drug Class
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Drug Class, 2017 to 2021
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug Class, 2022 to 2032
5.3.1. H2 (histamine-2) Blockers
5.3.2. Tyrosine Kinase Inhibitors
5.3.3. Alkylating Antineoplastic Agents
5.3.4. Corticosteroids
5.3.5. Other Drug Classes
5.4. Y-o-Y Growth Trend Analysis By Drug Class, 2017 to 2021
5.5. Absolute $ Opportunity Analysis By Drug Class, 2022 to 2032 Deep-dive segmentation will be available in the sample on request
6. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Route of Administration
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By Route of Administration, 2017 to 2021
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Route of Administration, 2022 to 2032
6.3.1. Oral
6.3.2. Injectable
6.4. Y-o-Y Growth Trend Analysis By Route of Administration, 2017 to 2021
6.5. Absolute $ Opportunity Analysis By Route of Administration, 2022 to 2032
7. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Distribution Channel
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Million) Analysis By Distribution Channel, 2017 to 2021
7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Distribution Channel, 2022 to 2032
7.3.1. Hospital Pharmacies
7.3.2. Retail Pharmacies
7.3.3. Drug Stores
7.3.4. Online Pharmacies
7.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2017 to 2021 Deep-dive segmentation will be available in the sample on request
7.5. Absolute $ Opportunity Analysis By Distribution Channel, 2022 to 2032
8. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Region
8.1. Introduction
8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2017 to 2021
8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2022 to 2032
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa
8.4. Market Attractiveness Analysis By Region
9. North America Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021
9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032
9.2.1. By Country
9.2.1.1. USA
9.2.1.2. Canada
9.2.2. By Drug Class
9.2.3. By Route of Administration
9.2.4. By Distribution Channel
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Drug Class
9.3.3. By Route of Administration
9.3.4. By Distribution Channel
9.4. Key Takeaways
10. Latin America Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032
10.2.1. By Country
10.2.1.1. Brazil
10.2.1.2. Mexico
10.2.1.3. Rest of Latin America
10.2.2. By Drug Class
10.2.3. By Route of Administration
10.2.4. By Distribution Channel
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Drug Class
10.3.3. By Route of Administration
10.3.4. By Distribution Channel
10.4. Key Takeaways
11. Europe Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032
11.2.1. By Country
11.2.1.1. Germany
11.2.1.2. United Kingdom
11.2.1.3. France
11.2.1.4. Spain
11.2.1.5. Italy
11.2.1.6. Russia
11.2.1.7. Rest of Europe
11.2.2. By Drug Class
11.2.3. By Route of Administration
11.2.4. By Distribution Channel
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Drug Class
11.3.3. By Route of Administration
11.3.4. By Distribution Channel
11.4. Key Takeaways
12. Asia Pacific Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032
12.2.1. By Country
12.2.1.1. China
12.2.1.2. Japan
12.2.1.3. India
12.2.1.4. South Korea
12.2.1.5. Australia
12.2.1.6. Rest of Asia Pacific
12.2.2. By Drug Class
12.2.3. By Route of Administration
12.2.4. By Distribution Channel
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Drug Class
12.3.3. By Route of Administration
12.3.4. By Distribution Channel
12.4. Key Takeaways
13. Middle East and Africa Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country
13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021
13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032
13.2.1. By Country
13.2.1.1. South Africa
13.2.1.2. Saudi Arabia
13.2.1.3. United Arab Emirates(UAE)
13.2.1.4. Israel
13.2.1.5. Rest of Middle East and Africa
13.2.2. By Drug Class
13.2.3. By Route of Administration
13.2.4. By Distribution Channel
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Drug Class
13.3.3. By Route of Administration
13.3.4. By Distribution Channel
13.4. Key Takeaways
14. Key Countries Market Analysis
14.1. USA
14.1.1. Pricing Analysis
14.1.2. Market Share Analysis, 2021
14.1.2.1. By Drug Class
14.1.2.2. By Route of Administration
14.1.2.3. By Distribution Channel
14.2. Canada
14.2.1. Pricing Analysis
14.2.2. Market Share Analysis, 2021
14.2.2.1. By Drug Class
14.2.2.2. By Route of Administration
14.2.2.3. By Distribution Channel
14.3. Brazil
14.3.1. Pricing Analysis
14.3.2. Market Share Analysis, 2021
14.3.2.1. By Drug Class
14.3.2.2. By Route of Administration
14.3.2.3. By Distribution Channel
14.4. Mexico
14.4.1. Pricing Analysis
14.4.2. Market Share Analysis, 2021
14.4.2.1. By Drug Class
14.4.2.2. By Route of Administration
14.4.2.3. By Distribution Channel
14.5. Germany
14.5.1. Pricing Analysis
14.5.2. Market Share Analysis, 2021
14.5.2.1. By Drug Class
14.5.2.2. By Route of Administration
14.5.2.3. By Distribution Channel
14.6. United Kingdom
14.6.1. Pricing Analysis
14.6.2. Market Share Analysis, 2021
14.6.2.1. By Drug Class
14.6.2.2. By Route of Administration
14.6.2.3. By Distribution Channel
14.7. France
14.7.1. Pricing Analysis
14.7.2. Market Share Analysis, 2021
14.7.2.1. By Drug Class
14.7.2.2. By Route of Administration
14.7.2.3. By Distribution Channel
14.8. Spain
14.8.1. Pricing Analysis
14.8.2. Market Share Analysis, 2021
14.8.2.1. By Drug Class
14.8.2.2. By Route of Administration
14.8.2.3. By Distribution Channel
14.9. Italy
14.9.1. Pricing Analysis
14.9.2. Market Share Analysis, 2021
14.9.2.1. By Drug Class
14.9.2.2. By Route of Administration
14.9.2.3. By Distribution Channel
14.10. Russia
14.10.1. Pricing Analysis
14.10.2. Market Share Analysis, 2021
14.10.2.1. By Drug Class
14.10.2.2. By Route of Administration
14.10.2.3. By Distribution Channel
14.11. China
14.11.1. Pricing Analysis
14.11.2. Market Share Analysis, 2021
14.11.2.1. By Drug Class
14.11.2.2. By Route of Administration
14.11.2.3. By Distribution Channel
14.12. Japan
14.12.1. Pricing Analysis
14.12.2. Market Share Analysis, 2021
14.12.2.1. By Drug Class
14.12.2.2. By Route of Administration
14.12.2.3. By Distribution Channel
14.13. India
14.13.1. Pricing Analysis
14.13.2. Market Share Analysis, 2021
14.13.2.1. By Drug Class
14.13.2.2. By Route of Administration
14.13.2.3. By Distribution Channel
14.14. South Korea
14.14.1. Pricing Analysis
14.14.2. Market Share Analysis, 2021
14.14.2.1. By Drug Class
14.14.2.2. By Route of Administration
14.14.2.3. By Distribution Channel
14.15. Australia
14.15.1. Pricing Analysis
14.15.2. Market Share Analysis, 2021
14.15.2.1. By Drug Class
14.15.2.2. By Route of Administration
14.15.2.3. By Distribution Channel
14.16. South Africa
14.16.1. Pricing Analysis
14.16.2. Market Share Analysis, 2021
14.16.2.1. By Drug Class
14.16.2.2. By Route of Administration
14.16.2.3. By Distribution Channel
14.17. Saudi Arabia
14.17.1. Pricing Analysis
14.17.2. Market Share Analysis, 2021
14.17.2.1. By Drug Class
14.17.2.2. By Route of Administration
14.17.2.3. By Distribution Channel
14.18. United Arab Emirates(UAE)
14.18.1. Pricing Analysis
14.18.2. Market Share Analysis, 2021
14.18.2.1. By Drug Class
14.18.2.2. By Route of Administration
14.18.2.3. By Distribution Channel
14.19. Israel
14.19.1. Pricing Analysis
14.19.2. Market Share Analysis, 2021
14.19.2.1. By Drug Class
14.19.2.2. By Route of Administration
14.19.2.3. By Distribution Channel
15. Market Structure Analysis
15.1. Competition Dashboard
15.2. Competition Benchmarking
15.3. Market Share Analysis of Top Players
15.3.1. By Regional
15.3.2. By Drug Class
15.3.3. By Route of Administration
15.3.4. By Distribution Channel
16. Competition Analysis
16.1. Competition Deep Dive
16.1.1. Pfizer Inc.
16.1.1.1. Overview
16.1.1.2. Product Portfolio
16.1.1.3. Profitability by Market Segments
16.1.1.4. Sales Footprint
16.1.1.5. Strategy Overview
16.1.1.5.1. Marketing Strategy
16.1.1.5.2. Product Strategy
16.1.1.5.3. Channel Strategy
16.1.2. Novartis AG
16.1.2.1. Overview
16.1.2.2. Product Portfolio
16.1.2.3. Profitability by Market Segments
16.1.2.4. Sales Footprint
16.1.2.5. Strategy Overview
16.1.2.5.1. Marketing Strategy
16.1.2.5.2. Product Strategy
16.1.2.5.3. Channel Strategy
16.1.3. Teva Pharmaceutical Industries Ltd.
16.1.3.1. Overview
16.1.3.2. Product Portfolio
16.1.3.3. Profitability by Market Segments
16.1.3.4. Sales Footprint
16.1.3.5. Strategy Overview
16.1.3.5.1. Marketing Strategy
16.1.3.5.2. Product Strategy
16.1.3.5.3. Channel Strategy
16.1.4. Glaxosmithkline Inc
16.1.4.1. Overview
16.1.4.2. Product Portfolio
16.1.4.3. Profitability by Market Segments
16.1.4.4. Sales Footprint
16.1.4.5. Strategy Overview
16.1.4.5.1. Marketing Strategy
16.1.4.5.2. Product Strategy
16.1.4.5.3. Channel Strategy
16.1.5. Eli Lilly and Company
16.1.5.1. Overview
16.1.5.2. Product Portfolio
16.1.5.3. Profitability by Market Segments
16.1.5.4. Sales Footprint
16.1.5.5. Strategy Overview
16.1.5.5.1. Marketing Strategy
16.1.5.5.2. Product Strategy
16.1.5.5.3. Channel Strategy
16.1.6. Bristol Myers Squibb Company
16.1.6.1. Overview
16.1.6.2. Product Portfolio
16.1.6.3. Profitability by Market Segments
16.1.6.4. Sales Footprint
16.1.6.5. Strategy Overview
16.1.6.5.1. Marketing Strategy
16.1.6.5.2. Product Strategy
16.1.6.5.3. Channel Strategy
16.1.7. Hikma Pharmaceuticals
16.1.7.1. Overview
16.1.7.2. Product Portfolio
16.1.7.3. Profitability by Market Segments
16.1.7.4. Sales Footprint
16.1.7.5. Strategy Overview
16.1.7.5.1. Marketing Strategy
16.1.7.5.2. Product Strategy
16.1.7.5.3. Channel Strategy
16.1.8. Jaapharm Canada Inc.
16.1.8.1. Overview
16.1.8.2. Product Portfolio
16.1.8.3. Profitability by Market Segments
16.1.8.4. Sales Footprint
16.1.8.5. Strategy Overview
16.1.8.5.1. Marketing Strategy
16.1.8.5.2. Product Strategy
16.1.8.5.3. Channel Strategy
16.1.9. Endo International
16.1.9.1. Overview
16.1.9.2. Product Portfolio
16.1.9.3. Profitability by Market Segments
16.1.9.4. Sales Footprint
16.1.9.5. Strategy Overview
16.1.9.5.1. Marketing Strategy
16.1.9.5.2. Product Strategy
16.1.9.5.3. Channel Strategy
16.1.10. Apotex Pharmaceutical Holdings Inc.
16.1.10.1. Overview
16.1.10.2. Product Portfolio
16.1.10.3. Profitability by Market Segments
16.1.10.4. Sales Footprint
16.1.10.5. Strategy Overview
16.1.10.5.1. Marketing Strategy
16.1.10.5.2. Product Strategy
16.1.10.5.3. Channel Strategy
16.1.11. Horizon Therapeutics plc
16.1.11.1. Overview
16.1.11.2. Product Portfolio
16.1.11.3. Profitability by Market Segments
16.1.11.4. Sales Footprint
16.1.11.5. Strategy Overview
16.1.11.5.1. Marketing Strategy
16.1.11.5.2. Product Strategy
16.1.11.5.3. Channel Strategy
17. Assumptions & Acronyms Used18. Research Methodology
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
List of Tables
Table 1: Global Market Value (US$ Million) Forecast by Region, 2017 to 2032
Table 2: Global Market Value (US$ Million) Forecast by Drug Class, 2017 to 2032
Table 3: Global Market Value (US$ Million) Forecast by Route of Administration, 2017 to 2032
Table 4: Global Market Value (US$ Million) Forecast by Distribution Channel, 2017 to 2032
Table 5: North America Market Value (US$ Million) Forecast by Country, 2017 to 2032
Table 6: North America Market Value (US$ Million) Forecast by Drug Class, 2017 to 2032
Table 7: North America Market Value (US$ Million) Forecast by Route of Administration, 2017 to 2032
Table 8: North America Market Value (US$ Million) Forecast by Distribution Channel, 2017 to 2032
Table 9: Latin America Market Value (US$ Million) Forecast by Country, 2017 to 2032
Table 10: Latin America Market Value (US$ Million) Forecast by Drug Class, 2017 to 2032
Table 11: Latin America Market Value (US$ Million) Forecast by Route of Administration, 2017 to 2032
Table 12: Latin America Market Value (US$ Million) Forecast by Distribution Channel, 2017 to 2032
Table 13: Europe Market Value (US$ Million) Forecast by Country, 2017 to 2032
Table 14: Europe Market Value (US$ Million) Forecast by Drug Class, 2017 to 2032
Table 15: Europe Market Value (US$ Million) Forecast by Route of Administration, 2017 to 2032
Table 16: Europe Market Value (US$ Million) Forecast by Distribution Channel, 2017 to 2032
Table 17: Asia Pacific Market Value (US$ Million) Forecast by Country, 2017 to 2032
Table 18: Asia Pacific Market Value (US$ Million) Forecast by Drug Class, 2017 to 2032
Table 19: Asia Pacific Market Value (US$ Million) Forecast by Route of Administration, 2017 to 2032
Table 20: Asia Pacific Market Value (US$ Million) Forecast by Distribution Channel, 2017 to 2032
Table 21: MEA Market Value (US$ Million) Forecast by Country, 2017 to 2032
Table 22: MEA Market Value (US$ Million) Forecast by Drug Class, 2017 to 2032
Table 23: MEA Market Value (US$ Million) Forecast by Route of Administration, 2017 to 2032
Table 24: MEA Market Value (US$ Million) Forecast by Distribution Channel, 2017 to 2032
Find your sweet spots for generating winning opportunities in this market.
List of Charts
Figure 1: Global Market Value (US$ Million) by Drug Class, 2022 to 2032
Figure 2: Global Market Value (US$ Million) by Route of Administration, 2022 to 2032
Figure 3: Global Market Value (US$ Million) by Distribution Channel, 2022 to 2032
Figure 4: Global Market Value (US$ Million) by Region, 2022 to 2032
Figure 5: Global Market Value (US$ Million) Analysis by Region, 2017 to 2032
Figure 6: Global Market Value Share (%) and BPS Analysis by Region, 2022 to 2032
Figure 7: Global Market Y-o-Y Growth (%) Projections by Region, 2022 to 2032
Figure 8: Global Market Value (US$ Million) Analysis by Drug Class, 2017 to 2032
Figure 9: Global Market Value Share (%) and BPS Analysis by Drug Class, 2022 to 2032
Figure 10: Global Market Y-o-Y Growth (%) Projections by Drug Class, 2022 to 2032
Figure 11: Global Market Value (US$ Million) Analysis by Route of Administration, 2017 to 2032
Figure 12: Global Market Value Share (%) and BPS Analysis by Route of Administration, 2022 to 2032
Figure 13: Global Market Y-o-Y Growth (%) Projections by Route of Administration, 2022 to 2032
Figure 14: Global Market Value (US$ Million) Analysis by Distribution Channel, 2017 to 2032
Figure 15: Global Market Value Share (%) and BPS Analysis by Distribution Channel, 2022 to 2032
Figure 16: Global Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022 to 2032
Figure 17: Global Market Attractiveness by Drug Class, 2022 to 2032
Figure 18: Global Market Attractiveness by Route of Administration, 2022 to 2032
Figure 19: Global Market Attractiveness by Distribution Channel, 2022 to 2032
Figure 20: Global Market Attractiveness by Region, 2022 to 2032
Figure 21: North America Market Value (US$ Million) by Drug Class, 2022 to 2032
Figure 22: North America Market Value (US$ Million) by Route of Administration, 2022 to 2032
Figure 23: North America Market Value (US$ Million) by Distribution Channel, 2022 to 2032
Figure 24: North America Market Value (US$ Million) by Country, 2022 to 2032
Figure 25: North America Market Value (US$ Million) Analysis by Country, 2017 to 2032
Figure 26: North America Market Value Share (%) and BPS Analysis by Country, 2022 to 2032
Figure 27: North America Market Y-o-Y Growth (%) Projections by Country, 2022 to 2032
Figure 28: North America Market Value (US$ Million) Analysis by Drug Class, 2017 to 2032
Figure 29: North America Market Value Share (%) and BPS Analysis by Drug Class, 2022 to 2032
Figure 30: North America Market Y-o-Y Growth (%) Projections by Drug Class, 2022 to 2032
Figure 31: North America Market Value (US$ Million) Analysis by Route of Administration, 2017 to 2032
Figure 32: North America Market Value Share (%) and BPS Analysis by Route of Administration, 2022 to 2032
Figure 33: North America Market Y-o-Y Growth (%) Projections by Route of Administration, 2022 to 2032
Figure 34: North America Market Value (US$ Million) Analysis by Distribution Channel, 2017 to 2032
Figure 35: North America Market Value Share (%) and BPS Analysis by Distribution Channel, 2022 to 2032
Figure 36: North America Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022 to 2032
Figure 37: North America Market Attractiveness by Drug Class, 2022 to 2032
Figure 38: North America Market Attractiveness by Route of Administration, 2022 to 2032
Figure 39: North America Market Attractiveness by Distribution Channel, 2022 to 2032
Figure 40: North America Market Attractiveness by Country, 2022 to 2032
Figure 41: Latin America Market Value (US$ Million) by Drug Class, 2022 to 2032
Figure 42: Latin America Market Value (US$ Million) by Route of Administration, 2022 to 2032
Figure 43: Latin America Market Value (US$ Million) by Distribution Channel, 2022 to 2032
Figure 44: Latin America Market Value (US$ Million) by Country, 2022 to 2032
Figure 45: Latin America Market Value (US$ Million) Analysis by Country, 2017 to 2032
Figure 46: Latin America Market Value Share (%) and BPS Analysis by Country, 2022 to 2032
Figure 47: Latin America Market Y-o-Y Growth (%) Projections by Country, 2022 to 2032
Figure 48: Latin America Market Value (US$ Million) Analysis by Drug Class, 2017 to 2032
Figure 49: Latin America Market Value Share (%) and BPS Analysis by Drug Class, 2022 to 2032
Figure 50: Latin America Market Y-o-Y Growth (%) Projections by Drug Class, 2022 to 2032
Figure 51: Latin America Market Value (US$ Million) Analysis by Route of Administration, 2017 to 2032
Figure 52: Latin America Market Value Share (%) and BPS Analysis by Route of Administration, 2022 to 2032
Figure 53: Latin America Market Y-o-Y Growth (%) Projections by Route of Administration, 2022 to 2032
Figure 54: Latin America Market Value (US$ Million) Analysis by Distribution Channel, 2017 to 2032
Figure 55: Latin America Market Value Share (%) and BPS Analysis by Distribution Channel, 2022 to 2032
Figure 56: Latin America Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022 to 2032
Figure 57: Latin America Market Attractiveness by Drug Class, 2022 to 2032
Figure 58: Latin America Market Attractiveness by Route of Administration, 2022 to 2032
Figure 59: Latin America Market Attractiveness by Distribution Channel, 2022 to 2032
Figure 60: Latin America Market Attractiveness by Country, 2022 to 2032
Figure 61: Europe Market Value (US$ Million) by Drug Class, 2022 to 2032
Figure 62: Europe Market Value (US$ Million) by Route of Administration, 2022 to 2032
Figure 63: Europe Market Value (US$ Million) by Distribution Channel, 2022 to 2032
Figure 64: Europe Market Value (US$ Million) by Country, 2022 to 2032
Figure 65: Europe Market Value (US$ Million) Analysis by Country, 2017 to 2032
Figure 66: Europe Market Value Share (%) and BPS Analysis by Country, 2022 to 2032
Figure 67: Europe Market Y-o-Y Growth (%) Projections by Country, 2022 to 2032
Figure 68: Europe Market Value (US$ Million) Analysis by Drug Class, 2017 to 2032
Figure 69: Europe Market Value Share (%) and BPS Analysis by Drug Class, 2022 to 2032
Figure 70: Europe Market Y-o-Y Growth (%) Projections by Drug Class, 2022 to 2032
Figure 71: Europe Market Value (US$ Million) Analysis by Route of Administration, 2017 to 2032
Figure 72: Europe Market Value Share (%) and BPS Analysis by Route of Administration, 2022 to 2032
Figure 73: Europe Market Y-o-Y Growth (%) Projections by Route of Administration, 2022 to 2032
Figure 74: Europe Market Value (US$ Million) Analysis by Distribution Channel, 2017 to 2032
Figure 75: Europe Market Value Share (%) and BPS Analysis by Distribution Channel, 2022 to 2032
Figure 76: Europe Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022 to 2032
Figure 77: Europe Market Attractiveness by Drug Class, 2022 to 2032
Figure 78: Europe Market Attractiveness by Route of Administration, 2022 to 2032
Figure 79: Europe Market Attractiveness by Distribution Channel, 2022 to 2032
Figure 80: Europe Market Attractiveness by Country, 2022 to 2032
Figure 81: Asia Pacific Market Value (US$ Million) by Drug Class, 2022 to 2032
Figure 82: Asia Pacific Market Value (US$ Million) by Route of Administration, 2022 to 2032
Figure 83: Asia Pacific Market Value (US$ Million) by Distribution Channel, 2022 to 2032
Figure 84: Asia Pacific Market Value (US$ Million) by Country, 2022 to 2032
Figure 85: Asia Pacific Market Value (US$ Million) Analysis by Country, 2017 to 2032
Figure 86: Asia Pacific Market Value Share (%) and BPS Analysis by Country, 2022 to 2032
Figure 87: Asia Pacific Market Y-o-Y Growth (%) Projections by Country, 2022 to 2032
Figure 88: Asia Pacific Market Value (US$ Million) Analysis by Drug Class, 2017 to 2032
Figure 89: Asia Pacific Market Value Share (%) and BPS Analysis by Drug Class, 2022 to 2032
Figure 90: Asia Pacific Market Y-o-Y Growth (%) Projections by Drug Class, 2022 to 2032
Figure 91: Asia Pacific Market Value (US$ Million) Analysis by Route of Administration, 2017 to 2032
Figure 92: Asia Pacific Market Value Share (%) and BPS Analysis by Route of Administration, 2022 to 2032
Figure 93: Asia Pacific Market Y-o-Y Growth (%) Projections by Route of Administration, 2022 to 2032
Figure 94: Asia Pacific Market Value (US$ Million) Analysis by Distribution Channel, 2017 to 2032
Figure 95: Asia Pacific Market Value Share (%) and BPS Analysis by Distribution Channel, 2022 to 2032
Figure 96: Asia Pacific Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022 to 2032
Figure 97: Asia Pacific Market Attractiveness by Drug Class, 2022 to 2032
Figure 98: Asia Pacific Market Attractiveness by Route of Administration, 2022 to 2032
Figure 99: Asia Pacific Market Attractiveness by Distribution Channel, 2022 to 2032
Figure 100: Asia Pacific Market Attractiveness by Country, 2022 to 2032
Figure 101: MEA Market Value (US$ Million) by Drug Class, 2022 to 2032
Figure 102: MEA Market Value (US$ Million) by Route of Administration, 2022 to 2032
Figure 103: MEA Market Value (US$ Million) by Distribution Channel, 2022 to 2032
Figure 104: MEA Market Value (US$ Million) by Country, 2022 to 2032
Figure 105: MEA Market Value (US$ Million) Analysis by Country, 2017 to 2032
Figure 106: MEA Market Value Share (%) and BPS Analysis by Country, 2022 to 2032
Figure 107: MEA Market Y-o-Y Growth (%) Projections by Country, 2022 to 2032
Figure 108: MEA Market Value (US$ Million) Analysis by Drug Class, 2017 to 2032
Figure 109: MEA Market Value Share (%) and BPS Analysis by Drug Class, 2022 to 2032
Figure 110: MEA Market Y-o-Y Growth (%) Projections by Drug Class, 2022 to 2032
Figure 111: MEA Market Value (US$ Million) Analysis by Route of Administration, 2017 to 2032
Figure 112: MEA Market Value Share (%) and BPS Analysis by Route of Administration, 2022 to 2032
Figure 113: MEA Market Y-o-Y Growth (%) Projections by Route of Administration, 2022 to 2032
Figure 114: MEA Market Value (US$ Million) Analysis by Distribution Channel, 2017 to 2032
Figure 115: MEA Market Value Share (%) and BPS Analysis by Distribution Channel, 2022 to 2032
Figure 116: MEA Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022 to 2032
Figure 117: MEA Market Attractiveness by Drug Class, 2022 to 2032
Figure 118: MEA Market Attractiveness by Route of Administration, 2022 to 2032
Figure 119: MEA Market Attractiveness by Distribution Channel, 2022 to 2032
Figure 120: MEA Market Attractiveness by Country, 2022 to 2032
